$14.18 Million in Sales Expected for Quanterix Corp (NASDAQ:QTRX) This Quarter

Share on StockTwits

Equities research analysts expect Quanterix Corp (NASDAQ:QTRX) to post $14.18 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Quanterix’s earnings. The highest sales estimate is $15.15 million and the lowest is $13.30 million. Quanterix reported sales of $10.88 million in the same quarter last year, which indicates a positive year over year growth rate of 30.3%. The company is scheduled to announce its next earnings results on Monday, March 16th.

According to Zacks, analysts expect that Quanterix will report full year sales of $54.96 million for the current financial year, with estimates ranging from $54.10 million to $55.87 million. For the next fiscal year, analysts expect that the business will report sales of $70.85 million, with estimates ranging from $68.05 million to $74.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Quanterix.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.01. Quanterix had a negative net margin of 75.78% and a negative return on equity of 54.74%. The business had revenue of $14.94 million for the quarter, compared to the consensus estimate of $12.52 million.

Several equities analysts have weighed in on the stock. Zacks Investment Research raised shares of Quanterix from a “sell” rating to a “hold” rating in a report on Tuesday, November 26th. Canaccord Genuity reaffirmed a “buy” rating and set a $35.00 price target on shares of Quanterix in a report on Thursday, November 7th.

In other news, SVP David C. Duffy sold 1,667 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.68, for a total value of $42,808.56. Also, CEO E Kevin Hrusovsky sold 3,336 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $21.78, for a total transaction of $72,658.08. Insiders have sold 16,656 shares of company stock worth $391,088 in the last ninety days. Insiders own 30.80% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Quanterix in the second quarter worth $76,000. Metropolitan Life Insurance Co NY purchased a new position in shares of Quanterix in the third quarter worth $78,000. Parametric Portfolio Associates LLC purchased a new position in shares of Quanterix in the second quarter worth $212,000. Royal Bank of Canada lifted its holdings in shares of Quanterix by 116.4% in the second quarter. Royal Bank of Canada now owns 6,285 shares of the company’s stock worth $213,000 after buying an additional 3,380 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Quanterix by 607.1% in the second quarter. Cubist Systematic Strategies LLC now owns 9,617 shares of the company’s stock worth $325,000 after buying an additional 8,257 shares in the last quarter. 67.50% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:QTRX traded down $0.77 during trading hours on Wednesday, hitting $24.14. 82,894 shares of the stock traded hands, compared to its average volume of 99,419. The company has a quick ratio of 7.00, a current ratio of 7.61 and a debt-to-equity ratio of 0.06. Quanterix has a 1 year low of $17.08 and a 1 year high of $36.15. The company has a market cap of $704.29 million, a price-to-earnings ratio of -16.88 and a beta of 1.36. The stock has a 50 day moving average price of $23.36 and a 200 day moving average price of $26.38.

About Quanterix

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

Featured Article: Initial Coin Offerings entail a high degree of risk

Get a free copy of the Zacks research report on Quanterix (QTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
PNM Resources Inc  Shares Sold by James Investment Research Inc.
PNM Resources Inc Shares Sold by James Investment Research Inc.
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc


© 2006-2020 Ticker Report